Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron Smith

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Analytical Chemistry|January 10, 2022
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal ImagingNicole Strittmatter, Frances M Richards, Alan M Race, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Science Translational Medicine|February 12, 2016
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivoSusan Ashton, Young Ho Song, Jim Nolan, et al.
Journal of Medicinal Chemistry|October 29, 2015
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular DiseasesRoger B Ruggeri, Leonard Buckbinder, Scott W Bagley, et al.
Science Advances|June 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor modelsStephen T Durant, Li Zheng, Yingchun Wang, et al.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIsNicola Colclough, Kan Chen, Peter Johnström, et al.
Communications Biology|May 13, 2024
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTACThomas G Hayhow, Beth Williamson, Mandy Lawson, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Analytical Chemistry|January 10, 2022
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal ImagingNicole Strittmatter, Frances M Richards, Alan M Race, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Science Translational Medicine|February 12, 2016
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivoSusan Ashton, Young Ho Song, Jim Nolan, et al.
Journal of Medicinal Chemistry|October 29, 2015
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular DiseasesRoger B Ruggeri, Leonard Buckbinder, Scott W Bagley, et al.
Science Advances|June 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor modelsStephen T Durant, Li Zheng, Yingchun Wang, et al.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIsNicola Colclough, Kan Chen, Peter Johnström, et al.
Communications Biology|May 13, 2024
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTACThomas G Hayhow, Beth Williamson, Mandy Lawson, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 17